Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Incidence of blood cancer is significantly higher in regions near facilities that release benzene

The incidence of a particular type of blood cancer is significantly higher in regions near facilities that release the chemical benzene into the environment. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. This and other studies like it will be critical to identifying and enacting public health policies to decrease or prevent cancer.

29 Jul 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.

24 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE).

17 Jul 2013

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

16 Jul 2013

Childhood cancer survivors can still get pregnant despite increased risk of infertility

Although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived, according to clinical researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Brigham and Women's Hospital. This is comparable to the rate of eventual pregnancy among all clinically infertile women.

15 Jul 2013

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.

11 Jul 2013

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

8 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Viewpoints: Controlling costs; Health law's guarantee of coverage; ACO liability

In the impassioned debates over healthcare, one fact is often lost - Americans pay more but get less for their health care than residents of other high-income countries. I believe we can change that. We can improve the quality of care and reduce our expenses, saving a trillion dollars or more a year, by making our health care system more efficient (William A. Haseltine, 6/17).

19 Jun 2013

Dosimetry based on 3-D medical images estimates possible dose for targeted RIT in blood cancer patients

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art 3D imaging could lead to more personalized and effective treatments to improve patients' chances of living longer without progression of their cancer, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

15 Jun 2013

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

MRI scans of children who have had chemotherapy can detect early changes in their hearts finds research in biomed Central's open access journal Journal of Cardiovascular Magnetic Resonance.

10 Jun 2013

Three easy steps for cancer survivorship

Incorporating just three easy steps into a daily routine can increase a cancer patient's chance at survival, according to a physician who specializes in cancer survivorship.

31 May 2013

Cancer experts to discuss latest developments and implications of cell therapies in oncology

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

23 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Incidence of blood cancer is significantly higher in regions near facilities that release benzene

Technique for developing more targeted drugs using molecular "robots"

Genentech announces that Phase III CLL11 study meets primary endpoint

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

Childhood cancer survivors can still get pregnant despite increased risk of infertility

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Viewpoints: Controlling costs; Health law's guarantee of coverage; ACO liability

Dosimetry based on 3-D medical images estimates possible dose for targeted RIT in blood cancer patients

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

Three easy steps for cancer survivorship

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Everything you should know about lymphoma eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in